Search research articles
Contact Us
Filters
Showing results (51-60 of 201) with videos related to
Page
of 21
Sort By:
Expert Review of Hematology
|
April 30, 2021
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia
Hanny Al-Samkari, Gerald A Soff
American Journal of Hematology
|
June 10, 2018
Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays
Hanny Al-Samkari, Stacy E Croteau
British Journal of Clinical Pharmacology
|
July 23, 2018
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia
Hanny Al-Samkari, David J Kuter
Journal of Oncology Practice
|
November 11, 2017
Anticoagulation and Enzalutamide: Caution Over Convenience
Hanny Al-Samkari, Jean M Connors
British Journal of Haematology
|
October 7, 2021
TPO versus TPO: the good, the bad, and the to be determined
Eun-Ju Lee, Hanny Al-Samkari
American Journal of Hematology
|
September 7, 2018
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia
Hanny Al-Samkari, David J Kuter
British Journal of Haematology
|
July 7, 2018
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia
Hanny Al-Samkari, David J Kuter
Expert Review of Hematology
|
April 11, 2023
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia
Andrew B Song, Hanny Al-Samkari
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 8, 2020
Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study
Hanny Al-Samkari, Stacy E Croteau
Expert Review of Clinical Immunology
|
July 6, 2022
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia
Andrew B Song, Hanny Al-Samkari
Page
of 21
Search research articles
Search
Showing results (51-60 of 201) with videos related to
Sort By:
Page
of 21
Expert Review of Hematology
|
April 30, 2021
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia
Hanny Al-Samkari, Gerald A Soff
American Journal of Hematology
|
June 10, 2018
Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays
Hanny Al-Samkari, Stacy E Croteau
British Journal of Clinical Pharmacology
|
July 23, 2018
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia
Hanny Al-Samkari, David J Kuter
Journal of Oncology Practice
|
November 11, 2017
Anticoagulation and Enzalutamide: Caution Over Convenience
Hanny Al-Samkari, Jean M Connors
British Journal of Haematology
|
October 7, 2021
TPO versus TPO: the good, the bad, and the to be determined
Eun-Ju Lee, Hanny Al-Samkari
American Journal of Hematology
|
September 7, 2018
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia
Hanny Al-Samkari, David J Kuter
British Journal of Haematology
|
July 7, 2018
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia
Hanny Al-Samkari, David J Kuter
Expert Review of Hematology
|
April 11, 2023
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia
Andrew B Song, Hanny Al-Samkari
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 8, 2020
Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study
Hanny Al-Samkari, Stacy E Croteau
Expert Review of Clinical Immunology
|
July 6, 2022
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia
Andrew B Song, Hanny Al-Samkari
Page
of 21